T cell subtype profiling measures exhaustion and predicts anti-PD-1 response
Ian Schillebeeckx(Cofactor Genomics (United States)), Jarret Glasscock(Cofactor Genomics (United States)), Kevin C. Flanagan, D. Messina(Cofactor Genomics (United States)), Jon R. Armstrong(Cofactor Genomics (United States)), Alex Bode(Cofactor Genomics (United States)), Ilaria Alborelli(ETH Zurich), Douglas R. Adkins(Washington University in St. Louis), Philip Jermann(Thermo Fisher Scientific (United States)), Jessica Ley(Washington University in St. Louis), Jeffrey Hiken(Cofactor Genomics (United States)), Jon Earls(Cofactor Genomics (United States))
Cited by 22
Related Papers
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
|The Lancet|2018|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial
|The Lancet Oncology|2013|748
NCCN Guidelines Insights: Head and Neck Cancers, Version 1.2018
|Journal of the National Comprehensive Cancer Network|2018|632